Co-morbid insomnia and sleep apnoea is associated with increased hypertension risk in a middle-aged population

Le résumé fourni par la source

Background: Emerging evidence suggests co-morbid insomnia and sleep apnoea (COMISA) is associated with increased risk of all-cause mortality. We studied the association between COMISA and hypertension in the Swedish CArdioPulmonary bioImaging Study (SCAPIS). Methods: Participants aged 50-64 years were randomly recruited from the general population. Information on anthropometrics, lifestyle, sleep, and comorbidities, was collected. Obstructive sleep apnoea (OSA) was assessed using a polygraphic device in a sub-cohort of SCAPIS (n=4286, 46% males, age 57.5±4.3 years, body mass index 26.6±4.3 kg/m2). COMISA was defined as apnoea-hypopnea index (AHI) >10 events/h and insomnia severity index score ≥15. Hypertension was defined as hypertension diagnosis with antihypertensive treatment. Results: COMISA was found in 12.8% of males and 19.8% of females with OSA (P=0.004). AHI was comparable between COMISA and OSA/no-insomnia groups (19±9 vs. 18±9 events/h, P=0.62). Difficulty initiating sleep, difficulty maintaining sleep, and early morning awakening ≥3 times/week was reported in 42.4, 84.3, and 51.1% of COMISA patients, respectively. Compared with non-OSA, OSA/no-insomnia and COMISA was associated with an increased risk of hypertension in a dose-dependent manner after controlling for confounders (odds ratio [95%CI]: 1.37 [1.10-1.69], 2.06 [1.37-3.10], P=0.004, <0.001, respectively). Conclusions: In this large population based study, we demonstrated the synergic effect of insomnia on cardiovascular complications in OSA. Adequate insomnia management should be considered for precision treatment of COMISA.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.